Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective are to assess the nature and incidence of drug intolerance observed with a new antiretroviral triple therapy, Truvada® [0-0-1] + Isentress® 400 mg tablets [1-0-1], prescribed in a setting of the treatment of individuals with recent exposure to a risk of transmission of HIV infection and to compare the results with those of previous studies conducted according to the same methodology, with other combinations of antiretrovirals.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Raltegravir Potassium

Criteria

Inclusion criteria

• age 18 years or over

• consultation immediately following exposure to the risk of transmission of HIV infection (less than 48 hours, except in the case of rape when this period may be increased to a maximum of 120 hours)

• person capable of understanding the principle of the study and giving his/her informed consent

Exclusion criteria

• subjects recently exposed to a risk of transmission of HIV infection in which the source patient is known to be infected with HIV and treated, and whose therapeutic history justifies the introduction of PET other than that proposed in this study

• subjects with a contraindication to the prescription of Truvada® and/or Isentress® (renal impairment, allergy, etc.)

• subjects previously treated with phenytoin, phenobarbital and rifampicin, since combination with raltegravir is contraindicated subjects known to be infected with hepatitis B virus, whether or not treated with lamivudine

• subjects refusing to take part in the study

• pregnant women